Healthcare Industry News: NUVIGIL
News Release - September 30, 2013
Alkermes Expands Senior Management TeamAppoints Serge Stankovic, M.D., as Senior Vice President of Clinical Development and Medical Affairs, and Peter Norman as Vice President of Government Affairs
DUBLIN--(Healthcare Sales & Marketing Network)--Alkermes plc (ALKS) today announced that it has expanded its senior management team by appointing two industry veterans to newly created roles. Srdjan (Serge) Stankovic, M.D., MSPH, will serve as Senior Vice President of Clinical Development and Medical Affairs, and Peter Norman has joined the company as Vice President of Government Affairs and Policy.
“We are very pleased to welcome Serge and Pete – two proven leaders whose expertise will contribute to Alkermes’ next stage of growth,” said Richard Pops, Chief Executive Officer of Alkermes. “As our portfolio of new medicines expands, we are responding by strengthening our capabilities in two areas critical for our future: global clinical development and government affairs.”
Dr. Serge Stankovic will be responsible for Alkermes’ Clinical Development and Medical Affairs function, which advances and implements the clinical development programs for the company’s pipeline of drug candidates. He will serve on the senior management team at Alkermes and report to Elliot Ehrich, M.D., Senior Vice President of Research & Development and Chief Medical Officer.
“I am very enthusiastic about leading the clinical development programs during this exciting time when Alkermes is expanding its pipeline,” said Dr. Stankovic. “I look forward not only to making progress with the range of clinical studies that are underway and planned for drug candidates, but also to achieving the ultimate goal of delivering valuable medicines that make a difference for patients.”
Mr. Peter Norman will lead Alkermes’ U.S. Government Affairs and Policy function, ranging from activities at federal and state levels, to interactions with professional and patient organizations. He will serve on the senior management team at Alkermes and report to Kathryn Biberstein, Senior Vice President, Chief Legal Officer and Chief Compliance Officer.
“I am excited to join Alkermes at a time when there are so many emerging opportunities to connect the company’s medicines with policy and advocacy initiatives to impact patients, healthcare systems and the public health,” said Mr. Norman. “Alkermes is poised to advance innovative solutions for chronic central nervous system (CNS) diseases that significantly impact both health systems and society. I also look forward to exploring new public affairs and policy strategies for enhancing adoption of, and access to, the company’s products.”
Dr. Serge Stankovic brings more than 20 years of research and development (R&D) experience to Alkermes. He has led multidisciplinary development teams for small molecules and biologics in the therapeutic areas of psychiatry, neurology, oncology, pain and inflammation, respiratory medicine, cardiovascular medicine and stem cell therapy. Most recently, Dr. Stankovic held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals. He was appointed to this role following Teva’s acquisition of Cephalon, Inc., where he served as Senior Vice President, Worldwide Clinical Research, and was a member of the Executive Committee. In addition, Dr. Stankovic has held various executive management positions in the R&D organizations of UCB Pharma, Johnson & Johnson, Neurogen Corporation and Forest Laboratories, Inc., and is credited with several major new drug approvals, including KEPPRA® and NUVIGIL®. Dr. Stankovic completed his training in psychiatry at the University of Belgrade, Yugoslavia and his epidemiology training at the University of Alabama in Birmingham.
Mr. Peter Norman is a seasoned government affairs leader with significant experience in legislative and regulatory efforts as well as interactions with patient groups and healthcare coalitions on behalf of biopharmaceutical companies. He has worked on public policy strategies related to a range of pharmaceutical products, including drugs for Alzheimer’s disease, obesity and diabetes, in addition to major healthcare issues, such as Medicare and Medicaid reimbursement, healthcare reform, DEA-controlled substance scheduling and biosimilars legislation. Most recently, Mr. Norman was head of the Washington, D.C. office of Eisai, Inc., where he directed government affairs and policy. Previously, he held government affairs positions for Amylin Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Novo Nordisk; and the Biotechnology Industry Organization (BIO). Mr. Norman earned a Juris Doctor from the University of Toledo College of Law in Ohio.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including those risks described in the company’s most recent Annual Report on Form 10-K and 10-K/A, which are filed with the Securities and Exchange Commission (“SEC”) and are available on the SEC’s website at www.sec.gov. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating any forward-looking information contained in this press release.
KEPPRA® is a registered trademark of the UCB Group of Companies. NUVIGIL® is a trademark of Cephalon, Inc., or its affiliates.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.